The Centre has issued a strict safety warning against the use of a commonly used cold and cough medicine combination in children below four years of age. The formulation contains chlorpheniramine maleate, an antihistamine, and phenylephrine hydrochloride, a decongestant commonly used to relieve nasal congestion.
Following recommendations from an expert committee and the Drugs Technical Advisory Board (DTAB), the government has directed that formulations containing this combination should not be used in children under four. Their manufacture and sale for this age group have also been restricted. Drug manufacturers have been instructed to carry a clear warning on packaging stating that the medicine should not be administered to children below four years.
The government has cited the availability of safer alternatives as one reason behind the decision. Experts also stress that children should not be treated as smaller versions of adults because drug requirements, dosage and effects can vary considerably according to age, weight and overall health.
Paediatricians generally advise parents not to administer cough and cold medicines to young children without medical guidance. Most childhood colds are caused by viruses and often improve on their own, meaning medication may not always be necessary.
Parents should also avoid giving multiple medicines without checking their ingredients, as different brands may contain the same active components. Accidental duplication can increase the risk of overdose.
Medical attention should be sought promptly if a child develops breathing difficulties, persistent fever, dehydration, unusual drowsiness, refuses food or fluids, or experiences worsening symptoms. The latest directive is therefore intended as a safety measure, reminding parents that medicines for children should be used only when appropriate and under professional guidance.
